Dear editor,

We are submitting a manuscript entitled “Advances in Autoimmune Diseases with CCL21/CCR7 Chemokine Axis” for your consideration for publication as a communication in **British Journal of Pharmacology**.

The type of manuscript is a review article. This article reviews CCL21/CCR7 chemokine axis with regulation role in autoimmune diseases. With the in-depth understanding of the pathological mechanism of autoimmune diseases, the involvement of chemokines and their receptors in the pathological process of autoimmune diseases has been extensively researched. We have summarized the regulation role of CCL21/CCR7 chemokine axis in autoimmune diseases in recent years. Furthermore, we describe the biological functions of CCL21/CCR7 chemokine axis for immune cell such as T/B cells, DCs and NK cells in autoimmune diseases. It is well aknowleged that CCL21/CCR7 chemokine axis plays an important role in cancers. Recent researches have found that CCL21/CCR7 chemokine axis can not only promote the proliferation and metastasis of tumor cells, but also promote the differentiation and migration of immune cells. CCL21/CCR7 chemokine axis is also widely expressed in non-lymph node tissues such as fibroblasts and smooth muscle nuclear endothelial cells, and is closely related to biological effects such as inflammation, smooth muscle cell proliferation and matrix remodeling. CCL21/CCR7 chemokine axis not only regulate the migration of immune cells during inflammation, but also are closely related to lymphoid tissues formation, maturation and transport of immune cells in autoimmune diseases. Under the regulation of CCL21/CCR7 chemokine axis, immune cells participate in a variety of physiological and pathological processes, such as cytoskeletal structure reconstruction, migration and infiltration to target organs, mediating stress response, infection, wound healing, T cell differentiation, lymphoid organ development, angiogenesis,and dendritic cell maturation in autoimmune diseases.

We hope submit the manuscript to **British Journal of Pharmacology**. And we also hope the submission to be attracted by you. More importantly, we are very grateful for your valuable suggestions. The work described has not been submitted elsewhere for publication, in whole or in part, and all the authors listed have approved the manuscript that is enclosed. We deeply appreciate your consideration of our manuscript, and we look forward to receiving comments from the reviewers. If you have any queries, please don’t hesitate to contact me at the address below!

Thank you and best regards.

Yours sincerely,

Corresponding author, Lingling Zhang

Anhui Medical University

Institute of Clinical Pharmacology

Tel: 86-551-6516-1206

Fax: 86-551-6516-1208

1. mail:llzhang@hotmail.com

Sep, 21, 2021